Pharma BD Deal Intelligence
A quiet bolt-on that stuck: Nature's Own/Cenovis/Ostelin remained core, growing Sanofi (then Opella) assets for 17 years with real capex behind them — never written down, never a standalone name in the failure column.
Full analysis, sources & comparables →CNBC reported Sanofi-Aventis paying $544M for Primary Health Care's Symbion Consumer unit, framing the deal as Sanofi's push into Australian/NZ consumer…
Retrospective Australian commentary characterized the Sanofi acquisition of Symbion Consumer as overpriced and questions the long-term value extraction by the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AUD 560M; Australia/NZ nutraceuticals & OTC (Natures Own, Cenovis); consumer healthcare
A quiet bolt-on that stuck: Nature's Own/Cenovis/Ostelin remained core, growing Sanofi (then Opella) assets for 17 years with real capex behind them — never written down, never a standalone name in the failure column.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) (this deal) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2008 deals · Sanofi-Aventis deals